Treatment outcome after failure of a first antiepileptic drug.

ABSTRACT:

Objectives

We assessed the likelihood of 12-month seizure remission and treatment failure after failure of a first antiepileptic drug, and identified factors influencing these outcomes.

Methods

SANAD (Standard and New Antiepileptic Drug) was a randomized controlled trial comparing monotherapy with standard and new antiepileptic drugs. Patients were followed up to study completion, even if they were switched from their randomized treatment. After a first treatment failure, we assessed the probability of 12-month seizure remission and treatment failure. Prognostic modeling identified predictors of these outcomes.

Results

Forty-four percent of patients in the SANAD trial had a first treatment failure. Seventy-five percent of these subsequently achieved 12-month remission

SUBMITTER: Bonnett LJ 

PROVIDER: S-EPMC4142004 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature